|Dr. Stephana E. Patton||Gen. Counsel, Corp. Sec. & Chief Compliance Officer||N/A||N/A||1971|
|Mr. Brian M. Culley||CEO, Pres & Director||549.21k||N/A||1971|
|Ms. Brandi L. Roberts||CFO & Sec.||N/A||N/A||1974|
|Ioana C. Hone||Director of Investor Relations||N/A||N/A||N/A|
|Mr. David Nakasone||Director of Investor Relations||N/A||N/A||N/A|
BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. The company has collaboration with Orbit Biomedical, Ltd. BioTime, Inc. was founded in 1990 and is headquartered in Alameda, California.
BioTime, Inc.’s ISS Governance QualityScore as of April 1, 2019 is 4. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 3; Compensation: 7.